About 3–12% of upper tract urothelial carcinomas (UTUC) exhibit dMMR, which most commonly manifests as a dual loss of MSH2 and MSH6 or isolated MSH6 loss (up to 86%) [25,65,66,67]. Here, MSH2 is linked to renal pelvis/ureter urothelial carcinoma.